liu.seSök publikationer i DiVA
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för inflammation och infektion. Linköpings universitet, Medicinska fakulteten.ORCID-id: 0000-0002-2125-2931
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för inflammation och infektion. Linköpings universitet, Medicinska fakulteten.
Linköpings universitet, Institutionen för biomedicinska och kliniska vetenskaper, Avdelningen för inflammation och infektion. Linköpings universitet, Medicinska fakulteten. Region Östergötland, Diagnostikcentrum, Klinisk immunologi och transfusionsmedicin.
Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden.
Visa övriga samt affilieringar
2020 (Engelska)Ingår i: Journal of Autoimmunity, ISSN 0896-8411, E-ISSN 1095-9157, Vol. 106, artikel-id 102340Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

Objective

The soluble urokinase plasminogen activator receptor (suPAR) has potential as a prognosis and severity biomarker in several inflammatory and infectious diseases. In a previous cross-sectional study, suPAR levels were shown to reflect damage accrual in cases of systemic lupus erythematosus (SLE). Herein, we evaluated suPAR as a predictor of future organ damage in recent-onset SLE.

Methods

Included were 344 patients from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort who met the 1997 American College of Rheumatology classification criteria with 5-years of follow-up data available. Baseline sera from patients and age- and sex-matched controls were assayed for suPAR. Organ damage was assessed annually using the SLICC/ACR damage index (SDI).

Results

The levels of suPAR were higher in patients who accrued damage, particularly those with SDI≥2 at 5 years (N = 32, 46.8% increase, p = 0.004), as compared to patients without damage. Logistic regression analysis revealed a significant impact of suPAR on SDI outcome (SDI≥2; OR = 1.14; 95% CI 1.03–1.26), also after adjustment for confounding factors. In an optimized logistic regression to predict damage, suPAR persisted as a predictor, together with baseline disease activity (SLEDAI-2K), age, and non-Caucasian ethnicity (model AUC = 0.77). Dissecting SDI into organ systems revealed higher suPAR levels in patients who developed musculoskeletal damage (SDI≥1; p = 0.007).

Conclusion

Prognostic biomarkers identify patients who are at risk of acquiring early damage and therefore need careful observation and targeted treatment strategies. Overall, suPAR constitutes an interesting biomarker for patient stratification and for identifying SLE patients who are at risk of acquiring organ damage during the first 5 years of disease.

Ort, förlag, år, upplaga, sidor
Elsevier, 2020. Vol. 106, artikel-id 102340
Nyckelord [en]
Biomarker; SLE; Organ damage; Prognosis; Outcome
Nationell ämneskategori
Reumatologi och inflammation
Identifikatorer
URN: urn:nbn:se:liu:diva-163458DOI: 10.1016/j.jaut.2019.102340ISI: 000508747000012PubMedID: 31629628Scopus ID: 2-s2.0-85073722485OAI: oai:DiVA.org:liu-163458DiVA, id: diva2:1393702
Anmärkning

Funding Agencies|Swedish Rheumatism Association; Region Ostergotland (ALF Grants); King Gustaf Vs 80-year Anniversary Foundation; King Gustaf V and Queen Victorias Freemasons Foundation; Versus ArthritisVersus Arthritis; NIHR Manchester Biomedical Research CentreNational Institute for Health Research (NIHR); NIHR/Welcome Trust Manchester Clinical Research Facility; Lupus UK; Sandwell and West Birmingham Hospitals NHS Trust; National Institute for Health Research (NIHR)/Wellcome Trust Birmingham Clinical Research Facility; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [8UL1TR000150]; National Research Foundation of KoreaNational Research Foundation of Korea [NRF-2017M3A9B4050335]

Tillgänglig från: 2020-02-17 Skapad: 2020-02-17 Senast uppdaterad: 2021-04-30Bibliografiskt granskad

Open Access i DiVA

fulltext(1405 kB)244 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1405 kBChecksumma SHA-512
87dabb85be61556318b6d986e26a0dbdc1efaf9886fe2e133690ffaefebfe1f6687cf237696e05ce83705135fd6f9800236099015de5333b525b9593a4e5870d
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMedScopus

Person

Dahle, CharlotteSjöwall, Christopher

Sök vidare i DiVA

Av författaren/redaktören
Enocsson, HelenaWirestam, LinaDahle, CharlotteWetterö, JonasSjöwall, Christopher
Av organisationen
Avdelningen för inflammation och infektionMedicinska fakultetenKlinisk immunologi och transfusionsmedicinReumatologiska kliniken i Östergötland
I samma tidskrift
Journal of Autoimmunity
Reumatologi och inflammation

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 244 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 156 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf